Iovance Biotherapeutics Inc banner

Iovance Biotherapeutics Inc
NASDAQ:IOVA

Watchlist Manager
Iovance Biotherapeutics Inc Logo
Iovance Biotherapeutics Inc
NASDAQ:IOVA
Watchlist
Price: 5.065 USD 10.59% Market Closed
Market Cap: $2B

Wall Street
Price Targets

IOVA Price Targets Summary
Iovance Biotherapeutics Inc

Wall Street analysts forecast IOVA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IOVA is 9.293 USD with a low forecast of 2.02 USD and a high forecast of 17.85 USD.

Lowest
Price Target
2.02 USD
60% Downside
Average
Price Target
9.293 USD
83% Upside
Highest
Price Target
17.85 USD
252% Upside
Iovance Biotherapeutics Inc Competitors:
Price Targets
CSGP
CoStar Group Inc
63% Upside
8841
TOC Co Ltd
26% Upside
ACIU
AC Immune SA
236% Upside
ESQ
Esquire Financial Holdings Inc
25% Upside
PTCT
PTC Therapeutics Inc
43% Upside

Revenue
Forecast

N/A
Past Growth
46% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
N/A
Past Growth
46% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

The compound annual growth rate of Iovance Biotherapeutics Inc's revenue for the next 3 years is 46%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-67%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-67%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is IOVA's stock price target?
Price Target
9.293 USD

According to Wall Street analysts, the average 1-year price target for IOVA is 9.293 USD with a low forecast of 2.02 USD and a high forecast of 17.85 USD.

What is Iovance Biotherapeutics Inc's Revenue forecast?
Projected CAGR
46%

The compound annual growth rate of Iovance Biotherapeutics Inc's revenue for the next 3 years is 46%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett